Antiviral peptides and means for treating herpes infections
US5066783A · kind A · utility
Inventors
Key dates
| Filing date | Sep 15, 1988 |
| Grant date | Nov 19, 1991 |
| Priority date | — |
| Expiry date | Sep 15, 2008 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are antiviral peptides of the formula A-R.sup.8 -R.sup.9 -R.sup.10 -R.sup.11 -R.sup.12 -R.sup.13 -R.sup.14 -R.sup.15 B wherein A is from zero up to seven amino acid residues and includes a terminal hydrogen or a terminal N-acyl, or A is a phenylpropionyl with optional substitution of the para position of the phenyl, R.sup.8, R.sup.9, R.sup.10, R.sup.13, R.sup.14 and R.sup.15 are various amino acid residues with the stipulation that one or more of the three amino acid residues immediately preceeding R.sup.11 and R.sup.12 are independently Val, D-Val, Nva, D-Nva, Leu, D-Leu, Nle, D-Nle, Ile or D-Ile, and B is hydroxy, amino or lower alkylamino. The antiviral activity of the peptides can be enhanced by combining them with a protease inhibitor. The peptides and the combination are useful for the treatment of herpes viral infections in mammals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.